There is a difference between: a. applicants for a grant; and, b. "grantees" (those who received a grant....no one knows, apparently, but Gates the identity of the
"grantees". There is a difference between: a. WHO and its protocols for considering applicants and awarding grants; and, b. Gates, a private foundation in its protocols, etc. WHO is quasi-public and, therefore, political considerations obtain. Gates can be quite limiting in setting criteria for those that get to the award stage. Seems to me that any system "not really suitable for undeveloped areas" would be screened out and not get an award.......having said all of this, none of us know and it is all speculation.....could be several more grantees or only one more.....all we really know is that Chembio said that it was "one of".......
Malaria should be added to the Febrile since fever is a common symptom. Then there is Ebola/Malaria (a recent requested multiplex). Then Ebola too added to Febrile/Malaria. I wonder how many multiplex they can handle in one cassette.
I hope they have calculated a level of confidence and are not taking shots in the dark. Since Febrile and Ebola got to the field test stage I assume they understand the potential for success and the potential performance. What they can not predetermine are the false positives. That's what field testing is for.
There will be lateral flow grantees and as you said some applicants will have product ideas that are not really suitable for undeveloped areas. That was the case with WHO Ebola applicants. Despite WHO placing a very explicit set of criteria for their dream test they received many that needed a computer. WHO basically described what only lateral flow/DPP could deliver in whole.
Even if 2015 rev's are so-so, Sperzel has so many projects in the works, that he's bound to hit on something. Obviously, febrile illness and malaria are the best prospects, but we shouldn't forget about DPP HIV-Syph internationally. If this product becomes as popular in a few other countries as it has been in Mexico, it could be a big revenue generator.
I really don't understand how this stock sits at under $4 given the possibilities, but what do I know.
No doubt there are others. Some of them will undoubtedly have the cumbersome electronic readers. Try getting one of those to work when the battery dies or when it falls into a big puddle or when there's a software problem or when someone just doesn't really know how to use the damn thing.
Also, if you can test for latent malarial infection AND HIV and syphilis at the same time, why wouldn't you?
Yes....very good news.........as I recall the release, however, it indicated that Chembio "was one" of those receiving grants. I wonder which co.s were the other(s).......I will check to see if the Gates foundation issues releases on these.....
Importantly, this is a challenge to detect asymptomatic cases. Much more difficult than detecting febrile malarial cases. However, I'm going to go ahead and state that CEMI already knows the test is sensitive enough to meet the challenge. This is a big deal, because malaria is so devastating and so widespread. If DPP malaria does successfully identify asymptomatic cases, we're talking 10's of millions of tests. You do the financial math.
The lottery ticket on this one is a super bargain at $3.65.
Looks like Larry Siebert is a pretty shrewd investor.
He sold the majority of his stake in CEMI at much higher levels in Q4 of last year.
Now the stock is back to where it was trading at 16 months ago.... as the new CEO tries to clean-up the Company and re-organize it into a much more effective sales effort.
Gonna take some time.
Miracles don't happen overnight.
Patience will be rewarded.
I don't know the terms......not sure anyone out here does......seems to me that getting all of the rights must be viewed by management as a good thing irrespective of a buy out....enhanced value must be contemplated or, hopefully, they would not do it........so....yes,.....if it enhances value could effect price and timing of offers...there are all kinds of options....maybe there is an acquirer that has conditioned any buyout on getting the agreement...who knows..?...."only the Shadow knows what evil lurks in the hearts of men"......(for anyone old enough to remember a pre-television radio program called "The Shadow").......
Yeah I agree a buyer could step up any time and assume the same agreement, but that's why I'm thinking a couple of years out. Is this just the first step in getting to the End Game of a much higher company value?
Well.....now that the Stature agreement has been formed......and the terms are known......any acquirer would assume that agreement even if CEMI were sold tomorrow......my point is....taking into consideration only the Stature agreement, an acquirer can do its due diligence and the company sold before June 2016. I think that there are other events that have to play out before the real value of CEMI will be known......primarily ramped up revenues and profits.
Just wondering is JS doing this, to set chembio up for a buy out end of next year or 2017? Cleans things up nicely between CEMI and SDS, for an acquirer or global sales.
Don't try to talk reasonable with IT MJ. It will only come back with a negative.
True, to Sono's point, Ebola cases are going away fast. But, Ebola is very contagious and deadly in a very short time. When EBOLA raises its head it is too late and testing needs to be available quickly. That means tests that are POC and have a long shelf life.
They will want to keep the shelves loaded.
As I posted prior, Ebola is not going to be a Chembio rocket. Licensing can be and HIV Oral (DPP) getting adopted is the biggest. Cancer could be huge.
Yes, I agree that it will have to be part of any febrile illness assay going forward, if only because early ID could possibly stop a recurrence of this latest epidemic. The problem is, can CEMI actually conduct trials in Africa right now, given the paucity of cases? As of this moment, there are five Ebola cases in all of Liberia. That's it.
In Siera Leone, they are down to eight new cases a day. This epidemic could flare again, but it seems to be all but over. That's a good thing, of course, but it's going to be tough for CEMI to run trials. Corgenix ran trials late last year. They were always a step ahead of CEMI, and that step might prove decisive.
Meanwhile, CEMI has gotten no money for Ebola. I would think that's because Corgenix and others vacuumed up all the dough early and often.
I really hesitate to get into this tiff.......but, 2 points: 1. We should be ecstatic that Ebola is waning in some places. 2. This is a disease that recycles and recycles........It is short sighted to believe that it has or is going away for the near or long term.
You make my point. The epidemic is pretty much over in Liberia and Guinea, and fading rapidly in Sierra Leone. GSK can give 10,000 people the vaccine, but if no one in the control group gets Ebola, they'll never know if it works.
CEMI has been moving fast of Ebola and febrile illness, but maybe not fast enough.
Oh Sono, you should wait longer between your Alias and using Sailings alias. You've done the Sono vs Sailing thing before. Didn't work well when you forgot what alias you were signed in as.
Sono, I agree, it will be tough to test Ebola with real people. The window is narrow; too early it doesn't test out, too late and, well, too late. At least they are in the fore front.
First. How many need to be tested and where are they. They need to be tested early. How many test units have to be made to cover the area?
HIV in the USA is also going to be very difficult to do testing going forward for new competitors. PEDs HIV is very low and PEDS also are hard to get to subscribe to testing programs.